Ethical issues raised by genetic testing with oligonucleotide microarrays

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 23, Issue 2, 2003, Pages 127-138

  Grody, Wayne W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Discrimination; DNA chip; Ethics; Eugenics; Microarray; Molecular genetic testing

Indexed keywords

OLIGONUCLEOTIDE;

ABORTION; AUTOMATION; DNA MICROARRAY; ECONOMICS; EMPLOYMENT; ETHICS; ETHNOLOGY; GENE; GENE REPLACEMENT THERAPY; GENE TECHNOLOGY; GENETIC PRIVACY; GENOTYPE; HUMAN; INSURANCE; MOLECULAR GENETICS; MUTATION; PHENOTYPE; PHYSICIAN; POPULATION; PRENATAL DIAGNOSIS; REIMBURSEMENT; RESEARCH; REVIEW;

CONFIDENTIALITY; EUGENICS; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; INFORMED CONSENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT EDUCATION; PREGNANCY; PREJUDICE; PRENATAL CARE; PRENATAL DIAGNOSIS;

EID: 0037320232     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:23:2:127     Document Type: Review

References (40)

1. Kevles, D.J. and Hood, L. (1992) The Code of Codes: Scientific and Social Issues in the Human Genome Project. Harvard University Press, Cambridge, MA.
2. Nuremberg Code. (1949) Trials of War Criminals Before the Nuernberg Military Tribunals Under Control Council Law No. 10, Vol. 2. U.S. Government Printing Office, Washington, DC.
3. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1979) The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. U.S. Department of Health, Education and Welfare, Washington, DC.
4. United States Department of Energy. (1997) Human Genome Program Report, Part 1: Overview and Progress. U.S. Department of Energy, Germantown, MD, pp. 18-19.
5. Grody, W.W., Kronquist, K.E., Lee, E.U., Edmond, J., and Rome, L.H. (1993) PCR-based cystic fibrosis carrier screening in a first-year medical student biochemistry laboratory. Am. J. Hum. Genet. 53, 1352-1355.
6. Giardiello, F.M., Brensinger, J.D., Petersen, et al. (1997) The use and interpretation of commerical APC gene testing for familial adenomatous polyposis. N. Engl. J. Med. 336, 823-827.
7. Grody, W.W. (1999) Cystic fibrosis: Molecular diagnosis, population screening, and public policy. Arch. Pathol. Lab. Med. 123, 1041-1046..
8. Grody, W.W. and Desnick, R.J. (2001) Cystic fibrosis population carrier screening: here at last - are we ready? Genet. Med. 3, 87-90.
9. Geller, G., Botkin, J.R., Green, M.J., et al. (1997) Genetic testing for susceptibility to adult-onset cancer: The process and content of informed consent. JAMA 277, 1567-1474.
10. Holtzman, N.A., Murphy, P.D., Watson, M.S., and Barr, P.A. (1997) Predictive genetic testing: From basic research to clinical practice. Science 278, 602-605.
11. Task Force on Genetic Testing. (1998) Promoting Safe and Effective Genetic Testing in the United States. Johns Hopkins University Press, Baltimore, MD.
12. Amos, J. and Patnaik, M. (2002) Commercial molecular diagnostics in the U.S.: The Human Genome Project to the clinical laboratory. Hum. Mutat. 19, 324-333.
13. American Society of Clinical Oncology. (1996) Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J. Clin. Oncol. 14, 81730-1736.
14. Grody, W.W., Cutting, G.R., Klinger, K.W., Richards, C.S., Watson, M.S., and Desnick, R.J. (2001) Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet. Med. 3, 149-154.
15. McCabe, L.L., Grody, W.W., Henker, B., et al. (2000) The UCLA experience in developing protocols for informed consent. Genet. Med. 2, 46.
16. National Committee for Clinical Laboratory Standards. (1999) Molecular Diagnostic Methods for Genetic Diseases: Approved Guidelines. National Committee for Clinical Laboratory Standards, Wayne, PA.
17. Shattuck-Eidens, D., Oliphant, A., McClure, M., et al. (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations: Risk factor analysis and implications for genetic testing. JAMA 278, 1242-1250.
18. Billings, P., Cohn, M., de Cuevas, M., Beckwith, J., Alper, J., and Natowicz, M. (1992) Discrimination as a consequence of genetic testing. Am. J. Hum. Genet. 50, 476-482.
19. Hudson, K.L., Rothenberg, K.H., Andrews, L.B., Kahn, M.J.E., and Collins, F.S. (1995) Genetic discrimination and health insurance: An urgent need for reform. Science 270, 391-393.
20. Reilly, P.R. (1998) Rethinking risks to human subjects in genetic research. Am. J. Hum. Genet. 63, 682-685.
21. Peterson, E.A., Milliron, K.J., Lewis, K.E., Goold, S.D., and Merajver, S.D. (2002) Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol. Biomarkers Prev. 11, 79-87.
22. Friedrich, M. J. (2002) Preserving privacy, preventing discrimination becomes the province of genetics experts. JAMA 288, 815-819.
23. Wang, L.W. (2002) The Privacy Rule: HIPAA standards for the privacy of individually identifiable health information. Empl. Benefits J. 27, 59-63.
24. Botkin, J.R., McMahon, W.M., Smith, K.R., and Nash, J.E. (1998) Privacy and confidentiality in the publication of pedigrees: A survey of investigators and biomedical journals. JAMA 279, 1808-1812.
25. Byers, P.H. and Ashkenas, J. (1998) Pedigrees - Publish? or perish the thought? Am. J. Hum. Genet. 63, 678-681.
26. Struewing, J.P., Abeliovich, D, Peretz, T., et al. (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet. 11, 198-200.
27. Foster, M.W., Bersten, D., and Carter, T.H. (1998) A model agreement for genetic research in socially identifiable populations. Am. J. Hum. Genet. 63, 696-702.
28. Juengst, E.T., (1998) Group identity and human diversity: Keeping biology straight from culture. Am. J. Hum. Genet. 63, 673-677.
29. Pembrey, M.E. (1998) In the light of preimplantation genetic diagnosis: Some ethical issues in medical genetics revisited. Eur. J. Hum. Genet. 6, 4-11.
30. Clayton, E.W., Steinberg, K.K., Khoury, M.J., et al. (1995) Informed consent for genetic research on stored tissue samples. JAMA 274, 1786-1792.
31. Knoppers, B.M. and Laberge, C.M. (1995) Research and stored tissues: Persons as sources, samples as persons? JAMA 274, 1806-1807.
32. Grody, W.W. (1995) Molecular pathology, informed consent, and the paraffin block. Diagn. Molec. Pathol. 4, 155-157.
33. Grizzle, W. Grody, W.W., Noll, W.W., et al. (1999) Recommended policies for uses of human tissue in research, education, and quality control. Arch. Pathol. Lab. Med. 123, 296-300.
34. American Society of Human Genetics. (1996) ASHG Report: Statement on informed consent for genetic research. Am. J. Hum. Genet. 59, 471-474.
35. Merz, J.F., Sankar, P., Taube, S.E., and LiVolsi, V. (1997) Use of human tissues in research: Clarifying clinician and researcher roles and information flows. J. Invest. Med. 45, 252-257.
36. Ault, A. (1999) NBAC issues biosamples report. Nature Med. 5, 974.
37. Grody, W.W., and Watson, M.S. (1997) Those elusive molecular diagnostics CPT codes. Diagn. Molec. Pathol. 6, 131-133.
38. Garrett, C.T. and Ferreira-Gonzalez, A. (1996) FDA regulation of analyte-specific reagents (ASRs): Implications for nucleic acid-based molecular testing. Diagn. Molec. Pathol. 5, 151-153.
39. Voelkerding, K.V. (2000) Finding a workable balance: regulation of genetic testing in the human genome era. J. Mol. Diagn. 2, 57-59.
40. Kleiner, K. (2002) Bad for your health: are gene patents stopping patients getting the latest tests? New Sci. 173, 6.